Last update: Feb. 15, 2016
Minimal risk for breastfeeding and infant.
H2-type histamine receptor antagonist with similar action than cimetidine.
It is excreted in breast milk in clinically non-significant amount, much less than the dose administered to newborns and infants with gastroesophageal reflux disorders.
Although it does not normally affect prolactin secretion, there have been several cases of galactorrhea. Still unknown whether it is due to Famotidine itself or to gastroesophageal reflux.
Famotidine, Nizatidine and Roxatidine are excreted into milk but in less proportion than Cimetidine or Ranitidine, which have been proposed as alternative to during lactation.
We do not have alternatives for Φαμοτιδίνη since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM